Figure 2.

Tofacitinib reduced phoshorylation of STAT3 in murine endometriotic lesions and uteri. (A) The ratio of phosphorylated signal transducer and activator of transcription pathway (pSTAT3) to GAPDH and pSTAT3 to STAT3 in endometriotic lesions. (B) The ratio of pSTAT3 to GAPDH and pSTAT3 to STAT3 in excised uterine horns. (C) Representative western blot for phosphorylated STAT3 (pSTAT3) levels, GAPDH, and total-STAT3 following treatment with vehicle or Tofacitinib via oral gavage for 4 weeks (see Supplementary Information for full western blot image). Results shown as mean ± SEM. *P < 0.05 versus stimulation only.